MedTrace Logo

An Explanatory Factors Analysis of Inflammatory Bowel Diseases(IBD's) Management Costs for Adults Patients Treated by Biotherapy and Followed at Nancy University Hospital

NCT03248024 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2017-08-14

No results posted yet for this study

Summary

The objective of this study is to analyze the factors influencing the medical and non-medical direct costs of patients treated with biotherapy during the last twelve months (infliximab or adalimumab), including biosimilars (infliximab biosimilars: Inflectra ™ and Remsima ™) for treating Crohn's desease or ulcerative colitis

Conditions

  • Inflammatory Bowel Diseases

Sponsors & Collaborators

  • HEVA - Lyon

    collaborator UNKNOWN

  • Central Hospital, Nancy, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-28
Primary Completion
2017-02-07
Completion
2017-02-07

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03248024 on ClinicalTrials.gov